Albert Wu, MD, PhD, a known recommend of the usage of stem mobile treatment to regard eye stipulations, will advise corporate’s building of ocular tissue rejuvenation therapeutics
MOUNTAIN VIEW, Calif., Aug. 22, 2022 /PRNewswire/ — Flip Biotechnologies, a mobile rejuvenation corporate growing novel mRNA drugs to treatment untreatable, age-related stipulations, nowadays introduced that Albert Wu, MD, PhD, will oversee its building of ophthalmic healing merchandise as an marketing consultant to the corporate.
A board-certified ophthalmologist and fellowship-trained specialist in oculoplastic and orbital surgical operation, Wu’s instructional paintings has excited by growing remedies for imaginative and prescient loss and eye illness.
At Flip Bio, he’ll shepherd paintings on TRN-004, a components to rejuvenate ocular tissues, together with corneal, limbal and conjunctival epithelial cells, in addition to corneal endothelial cells. Preclinical effects display the components reduces irritation, oxidative pressure, and mobile senescence.
TRN-004 is a adapted protein cocktail to rejuvenate centered cells within the eye. It’s produced the usage of Flip Bio’s distinctive mRNA-based ERA™ (Epigenetic Reprogramming of Ageing) platform.
“Albert’s existence undertaking is to turn into ophthalmology by way of making regenerative medication an accredited remedy for other folks international affected by illnesses of the attention,” stated Anja Krammer, the corporate’s CEO. “His imaginative and prescient and revel in will assist us redefine how eye medical doctors deal with age-related imaginative and prescient stipulations for which no actual treatment exists.”
Wu has just about 20 years of revel in with ophthalmology and mobile biology. He has been commemorated by way of the Nationwide Institutes of Well being, American Society of Ophthalmic Plastic and Reconstructive Surgical operation, Icahn Faculty of Drugs at Mount Sinai, the College of Washington and Yale College.
“Our paintings has the possible to revolutionize eye care to maintain sufferers’ imaginative and prescient and, in the long run, repair it,” stated Wu. “The power to supply mobile rejuvenation treatments and ship them with pinpoint accuracy gives monumental promise to thousands and thousands of other folks around the globe whose sight has been compromised by way of untreatable stipulations.”
Wu won his bachelor’s stage in Molecular Biophysics and Biochemistry from Yale College, his scientific stage and doctoral stage in Molecular and Cell Biology from the College of Washington. He has co-authored 55 articles on his analysis discoveries and has contributed to textbooks on ophthalmology and ophthalmologic oncology. He’s a common presenter at nationwide and world scientific meetings.
ABOUT TURN BIOTECHNOLOGIES
Flip Bio is a pre-clinical-stage corporate excited by repairing tissue on the mobile degree. The corporate’s proprietary mRNA platform era, ERA™, restores optimum gene expression by way of combatting the consequences of getting old within the epigenome. This restores the cells’ talent to stop or deal with illness, heal or regenerate tissue and struggle incurable continual illnesses.
The corporate is these days finishing pre-clinical analysis on adapted treatments concentrated on indications in dermatology and immunology, in addition to growing treatments for ophthalmology, osteo-arthritis and the muscular gadget. For more info, see www.flip.bio.
FOR MORE INFORMATION, CONTACT:
Jim Martinez, rightstorygroup
[email protected] or (312) 543-9026
Picture – https://mma.prnewswire.com/media/1882156/Albert_Wu_Turn_Biotechnologies.jpg
SOURCE Flip Biotechnologies, Inc.
